AEM vs ASM

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

ASM presents a paradoxical profile with a stable Piotroski F-Score of 4/9 and exceptional balance sheet health, yet it trades at a significant premium to its Graham Number ($2.35) and Intrinsic Value ($5.02). While YoY earnings growth is explosive (82.90%) and margins are robust, the company has failed to beat earnings estimates in the last four consecutive quarters with a severe average surprise of -30.56%. The stark contrast between the 'Strong Buy' analyst consensus and the bearish technical trend/poor earnings track record suggests a high-risk growth play dependent on future production targets rather than current execution.